Johnson & Johnson’s first-in-class, bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell-redirecting, with weight-based dosing bispecific antibody which is administered as a subcutaneous treatment, is now available in Singapore.

This treatment was approved by Singapore’s Health Sciences Authority in February 2024. Singapore is the first country in Southeast Asia to approve and make this treatment available.

It is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma, who have received at least three prior therapies, including a proteasome inhibitor, an immunomodulatory agent and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy. This off-the-shelf (or ready to use) therapy uses innovative science to activate the immune system by binding to the CD3 receptor expressed on the surface of T-cells and to the B-cell maturation antigen expressed on the surface of multiple myeloma cells and some healthy B-lineage cells.

Globally, this treatment is the J&J's fourth approved treatment for multiple myeloma, further diversifying the company’s industry-leading oncology portfolio and deepening its commitment to discovering and developing therapies for this rare blood cancer.

Dr Premila Paranchothy, Head of Medical Affairs, Southeast Asia & India, Johnson & Johnson said “In Southeast Asia, Johnson & Johnson is a market leader in the multiple myeloma space and the availability of this B-cell maturation antigen (BCMA)-directed CD3 T-cell-redirecting bispecific antibody which is the first-in-class in Singapore, underscores our commitment to ensure that we are addressing and transforming outcomes for patients with multiple myeloma.”